[Progress on carboxyl-substituted phthalocyanine photosen-sitizers and their drug delivery systems for photodynamic therapy]
- PMID: 40603269
- DOI: 10.3724/zdxbyxb-2024-0687
[Progress on carboxyl-substituted phthalocyanine photosen-sitizers and their drug delivery systems for photodynamic therapy]
Abstract
Research in photodynamic therapy (PDT) primarily focuses on enhancing light penetration depth, improving oxygen supply, and optimizing photosensitizer delivery. Notably, the delivery efficiency of the photosensitizer is crucial for therapeutic efficacy. Carboxyl-substituted phthalocyanines, as important photosensitizing molecules, possess unique chemical modification sites that enable direct targeted delivery or integration into diverse delivery systems. Their synthesis predominantly employs mixed- or cross-condensation, selective synthesis, and axial modification strategies to introduce carboxyl groups. However, their inherent hydrophobicity significantly hinders effective delivery. To address this limitation, modifications with peptides or quaternary ammonium salt derivatives may facilitate precise delivery to tumor cells and pathogens. With advances in nanotechnology, carboxyl-substituted phthalocyanines can serve as key photosensitizer modules, effectively integrated into nanomaterials such as biomacromolecules, inorganic metals, and polymers for both active and passive delivery. Recently, researchers have exploited the π-π stacking and other intermolecular forces among carboxyl-substituted phthalocyanine molecules to drive their self-assembly into nano-micelles, enabling carrier-free delivery or co-delivery with other therapeutic agents for synergistic effects. This review systematically outlines the synthesis strategies for carboxyl-substituted phthalo-cyanines. Taking mono-carboxyl-substituted zinc phthalocyanine as a model molecule, the performance of three delivery modalities were compared: single-molecule targeted delivery, nanocarrier-encapsulated delivery, and carrier-free self-assembled delivery, in terms of PDT efficacy, biocompatibility, and imaging-guided tracing capabilities, to provide a systematic technical framework for the rational design of novel modular photosensitizers and to advance the clinical translation of PDT in precision oncology and anti-infective therapy.
光动力疗法研究的核心通常聚焦于提高光源穿透深度、改善氧气供给以及优化光敏剂递送这三大要素。其中,光敏剂的递送效率是决定光动力疗法效果的关键。羧基取代酞菁作为一类重要光敏分子,凭借其独特的化学修饰位点,可通过靶向修饰直接实现递送,或作为功能模块嵌入多元化的递送系统。其合成主要采用混合或交叉缩合反应法、选择性合成法及轴向修饰法引入羧基基团。然而,羧基取代酞菁固有的疏水性仍显著制约其有效递送。为克服其成药性不足的局限,可利用多肽或季铵盐衍生物进行修饰,从而实现靶向肿瘤细胞和致病菌的分子递送。随着纳米技术的发展,羧基取代酞菁可作为核心光敏剂模块,有效整合嵌入生物大分子、无机金属以及高分子聚合物等纳米材料中,借助这些纳米载体,可实现光敏剂的主动与被动递送。近年来,为提高药物利用度,研究者利用羧基取代酞菁分子间的π-π堆叠效应及其他分子间作用力,驱动其自组装形成纳米胶束。该策略实现了光敏剂的无载体递送,或与其他治疗药物联合递送以达成协同治疗。本综述系统阐述羧基取代酞菁的合成策略,并以单羧基取代酞菁锌为模型分子,比较单分子靶向递送、纳米载体包裹递送和无载体自组装递送三种递送模式在光动力治疗效能、生物相容性及成像示踪能力等方面的表现,旨在为新型模块化光敏剂的理性设计提供系统性技术框架,并为光动力疗法在精准肿瘤治疗及抗感染领域的临床转化开辟新路径。.
Keywords: Carboxyl-substituted phthalocyanine; Drug delivery system; Microbial infection; Oncologic therapy; Photodynamic therapy; Review.
Similar articles
-
Blackberry-Like Doxorubicin Loaded Hyaluronic Acid/Zinc Phthalocyanine Loaded Mesoporous Silica Nanocomposites for Long-Term Tumor Photodynamic and Chemotherapy Synergistic Therapy.Int J Nanomedicine. 2025 Jul 17;20:9111-9134. doi: 10.2147/IJN.S530041. eCollection 2025. Int J Nanomedicine. 2025. PMID: 40692537 Free PMC article.
-
2D and 3D in vitro photodynamic activities of tetra-substituted symmetric water-soluble cationic zinc(II) phthalocyanines on cancer.Sci Rep. 2025 Jul 11;15(1):25148. doi: 10.1038/s41598-025-09630-7. Sci Rep. 2025. PMID: 40646060 Free PMC article.
-
Innovative approaches for cancer treatment: graphene quantum dots for photodynamic and photothermal therapies.J Mater Chem B. 2024 May 8;12(18):4307-4334. doi: 10.1039/d4tb00255e. J Mater Chem B. 2024. PMID: 38595268 Review.
-
A mono-substituted aluminum phthalocyanine photosensitizer with high phototoxicity index for effective bladder cancer treatment.Bioorg Chem. 2025 Aug;163:108730. doi: 10.1016/j.bioorg.2025.108730. Epub 2025 Jul 5. Bioorg Chem. 2025. PMID: 40644816
-
Management of urinary stones by experts in stone disease (ESD 2025).Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085. Epub 2025 Jun 30. Arch Ital Urol Androl. 2025. PMID: 40583613 Review.
References
-
- BALAKIRSKI G, LEHMANN P, SZEIMIES R M, et al. Photodynamic therapy in dermatology: established and new indications[J]. J Dtsch Dermatol Ges, 2024, 22(12): 1651- 1662. /mixed-citation>
-
- GARG S J, HADZIAHMETOVIC M. Verteporfin photo-dynamic therapy for the treatment of chorioretinal condi-tions: a narrative review[J]. Clin Ophthalmol, 2024, 18: 1701- 1716. /mixed-citation>
-
- SUŁEK A, PUCELIK B, KOBIELUSZ M, et al. Photody-namic inactivation of bacteria with porphyrin deriva-tives: effect of charge, lipophilicity, ROS generation, and cellular uptake on their biological activity in vitro[J]. Int J Mol Sci, 2020, 21(22): 8716. /mixed-citation>
-
- PAN P, SVIRSKIS D, REES S W P, et al. Photosensi-tive drug delivery systems for cancer therapy: mecha-nisms and applications[J]. J Control Release, 2021, 338: 446- 461. /mixed-citation>
-
- LI Y, DU L, LI F, et al. Intelligent nanotransducer for deep-tumor hypoxia modulation and enhanced dual-photosensitizer photodynamic therapy[J]. ACS Appl Mater Interfaces, 2022, 14(13): 14944- 14952. /mixed-citation>
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous